Navigation Links
Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
Date:1/7/2011

SAN FRANCISCO, Jan. 7, 2011 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company has entered into a multi-year collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics.

Under the terms of the agreement, Sutro Biopharma will receive an upfront payment of an undisclosed amount, and Pfizer will provide Sutro with ongoing research funding. Sutro is eligible to receive development milestone payments and royalties upon commercialization of any products that may result from the collaboration. Additional details of the partnership were not disclosed.

"We are pleased to enter into this collaboration with Pfizer because it provides validation for the potential of our technology platform," said William Newell, chief executive officer of Sutro Biopharma. "This is another milestone in the maturation of the company as we move toward identification of our first drug candidates."

Sutro Biopharma recently secured $36.5 million in a Series C financing and announced the appointment of Trevor Hallam, Ph.D., as chief scientific officer. This is the first major collaboration announced by the company.

"This partnership gives Pfizer access to peptides that have been difficult to produce using conventional technologies," said Jaume Pons, Ph.D., vice president and chief scientific officer at Pfizer's Rinat subsidiary. "Sutro's open biochemical protein synthesis technology platform potentially resolves many of the problems inherent in other approaches, and we are looking forward to the mutual success of our collaboration."

About Sutro BiopharmaSutro Biopharma is a biopharmaceutical company that develops and designs novel protein therapeutics and biosuperiors that have site-directed modifications, including modifications incorporating non-natural amino acids. Sutro's biochemical protein synthesis technology opens up opportunities to create protein therapeutics that cannot be produced using conventional methods. Sutro's technology enables the rapid and systematic exploration of many protein drug variants to identify drug candidates. Once identified, the company can efficiently scale production to commercial levels. In addition to developing its own drug pipeline, Sutro is collaborating with select pharmaceutical and biotechnology companies in the development of novel protein therapeutics that cannot be designed, produced or studied with current technologies.Media Contacts:David Schull or Martina Schwarzkopf, Ph.D.Russo Partners(212) 845-4271 (212) 845-4292 (347) 591-8785 (mobile)david.schull@russopartnersllc.commartina.schwarzkopf@russopartnersllc.com
'/>"/>

SOURCE Sutro Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Ondine Biopharma Announces Second Quarter 2008 Financial Results
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
7. Therapure Biopharma Inc. opens for business with first client contracts
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. China Biopharma Effects 1 for 100 Reverse Stock Split
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... Chef Jodi Abel has returned from her three-week tour through the ... a number of delicious recipes and new techniques to share with her Lajollacooks4u guests. ... province. It is internationally renowned for its incredible wine farms, beautiful environment, boutiques ...
(Date:2/24/2017)... , Feb. 24, 2017  Driven by consumers, ... are now the fastest growing categories, finds the ... Actives in Personal Care: Multi-regional Market Analysis and ... management consulting firm Kline. "Biotechnology actives ... make them more effective for skin and hair ...
(Date:2/24/2017)... Pa., Feb. 24, 2017  VWR Corporation (NASDAQ: VWR), the ... laboratory and production customers, today reported its financial results for ... Highlights: 4Q16 record quarterly ... 1.0% on an organic basis. ... an organic basis, while the Americas net sales increased 2.5%, ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs ... to include an array of biochemical analyses critical for Lead Discovery. The ... hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, and ...
Breaking Biology Technology:
(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
(Date:1/26/2017)... -- Crossmatch, a leading provider of security and identity management ... fraud, waste and abuse in assistance operations around the ... Disaster Relief conference in Panama City ... foreign assistance organizations throughout Latin America ... largely unacknowledged problem in the foreign assistance and disaster ...
(Date:1/23/2017)... Jan. 23, 2017  The latest mobile market research ... have dropped dramatically. The quarterly average price of a ... $276 in Q4 2016.  There are now 120 sub-$150 ... $116, up from just 28 a year ago at ... to Maxine Most , Acuity Market Intelligence Principal, ...
Breaking Biology News(10 mins):